Axar.az
UP

Axar.Az Logo

Kenya launches cervical cancer vaccine

Home page Health
12 Punto 14 Punto 16 Punto 18 Punto

According to WHO, cervical cancer is third leading cause of deaths among women in Kenya.

Axar.az reports citing AA that Kenya on Wednesday launched a cervical cancer vaccine that targets over 800,000 girls above the age of 10 years in its first phase of operation.

Kenya’s Health Minister Sicily Kariuki, who presided over the launch, said the vaccine will help saving hundreds of thousands of lives in Kenya by fighting cancer.

According to the World Health Organization, cervical cancer is the third leading cause of deaths among women in Kenya after infectious and cardiovascular diseases.

“It [the vaccine] will protect children and adults from diseases, as well as prevent lifelong disabilities and in extreme cases deaths,” Kariuki said.

She added that Kenya will introduce the new vaccine to its routine immunization schedules with immediate effect. The first phase of the vaccine distribution exercise will cost the East African country 800 million Kenya shillings ($7.7 million) for the year 2019 only.

“The vaccine will be offered across the nation and it will be administered along with routine infant vaccines in over 9,000 public, private and faith-based health facilities and it will be offered free of charge,” Kariuki said.

Kariuki said that the Ministry of Health has 1.3 million doses of the vaccine which is way above the target of the 800,000 girls for the year 2019.

“The cervical cancer vaccine is safe, it is effective, it has been evaluated and licensed for use in this country and countries across the globe,” Kariuki said.

Date
2019.10.19 / 17:14
Author
Axar.az
Comments
See also

Britain abolished the masks and social distance rules

Number of people infected with coronavirus reaches 190 million

UK health minister gets COVID ahead of 'freedom day'

More dangerous variants of the corona will emerge - WHO

WHO: COVID-19 caused over 4 million deaths worldwide

Azerbaijan and Russia have signed an agreement

Pfizer-BioNTech is 70% effective against Delta variant

US allocates an additional $1M to Azerbaijan

COVAX calls on states: Vaccinated...

3 main symptoms of Delta Plus: The vaccine does not protect...

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla